Insider Trading Alert - HNT, SPNC And MEAS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 17, 2014, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.29 to $336,996,000.00.

Highlighted Stocks Traded by Insiders:

Health Net (HNT) - FREE Research Report

Tough Steven D, who is Pres, Govt Progrms at Health Net, sold 10,000 shares at $46.09 on Sept. 17, 2014. Following this transaction, the Pres, Govt Progrms owned 105,669 shares meaning that the stake was reduced by 8.65% with the 10,000-share transaction.

The shares most recently traded at $46.76, up $0.67, or 1.43% since the insider transaction. Historical insider transactions for Health Net go as follows:

  • 4-Week # shares sold: 25,473
  • 12-Week # shares sold: 25,473
  • 24-Week # shares sold: 25,473

The average volume for Health Net has been 946,100 shares per day over the past 30 days. Health Net has a market cap of $3.7 billion and is part of the health care sector and health services industry. Shares are up 57.06% year-to-date as of the close of trading on Tuesday.

Health Net, Inc. provides managed health care services through health plans and government-sponsored managed care plans in the United States. It operates through Western Region Operations and Government Contracts segments. The company has a P/E ratio of 15.7. Currently, there are 3 analysts who rate Health Net a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HNT - FREE

TheStreet Quant Ratings rates Health Net as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Health Net Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Spectranetics (SPNC) - FREE Research Report

Ruggio Joseph M, who is Director at Spectranetics, sold 10,000 shares at $28.19 on Sept. 17, 2014. Following this transaction, the Director owned 57,197 shares meaning that the stake was reduced by 14.88% with the 10,000-share transaction.

The shares most recently traded at $27.87, down $0.32, or 1.17% since the insider transaction. Historical insider transactions for Spectranetics go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Spectranetics has been 516,300 shares per day over the past 30 days. Spectranetics has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are up 12.44% year-to-date as of the close of trading on Tuesday.

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Currently, there are 8 analysts who rate Spectranetics a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPNC - FREE

TheStreet Quant Ratings rates Spectranetics as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Spectranetics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Measurement Specialties (MEAS) - FREE Research Report

Topfer Morton L, who is Director at Measurement Specialties, sold 32,039 shares at $85.80 on Sept. 17, 2014. Following this transaction, the Director owned 337,043 shares meaning that the stake was reduced by 8.68% with the 32,039-share transaction.

The shares most recently traded at $85.77, down $0.03, or 0.04% since the insider transaction. Historical insider transactions for Measurement Specialties go as follows:

  • 4-Week # shares sold: 119,513
  • 12-Week # shares sold: 119,513
  • 24-Week # shares sold: 119,513

The average volume for Measurement Specialties has been 173,600 shares per day over the past 30 days. Measurement Specialties has a market cap of $1.4 billion and is part of the technology sector and electronics industry. Shares are up 41.36% year-to-date as of the close of trading on Tuesday.

Measurement Specialties, Inc. designs, develops, and manufactures sensors and sensor-based systems for original equipment manufacturers and end users. The company has a P/E ratio of 48.7. Currently, there are no analysts who rate Measurement Specialties a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MEAS - FREE

TheStreet Quant Ratings rates Measurement Specialties as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Measurement Specialties Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%